Design, synthesis and biological evaluation of a novel series of anthrapyrazoles linked with netropsin-like oligopyrrole carboxamides as anticancer agents

Bioorganic and Medicinal Chemistry

Volumn 18, Issue 11, 2010, Pages 3974-3984

  Zhang, Rui ^a   Wu, Xing ^a   Guziec, Lynn J ^b   Guziec, Frank S ^b   Chee, Gaik Lean ^a   Yalowich, Jack C ^c   Hasinoff, Brian B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b SOUTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Anthrapyrazole; Anticancer; Cytotoxic; DNA; Intercalator; Minor groove; Netropsin; Topoisomerase I; Topoisomerase II

Indexed keywords

2 (2 AMINOETHYL)ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; 2 (2 HYDROXYETHYL)ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; 4 [[(4 AMINO 1 METHYL 2 PYRROLYL)CARBONYL]AMINO] N [2 (6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL)ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[(4 AMINO 1 METHYL 2 PYRROLYL)CARBONYL]AMINO] N [2 (7 CHLORO 6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL)ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[(TERT BUTOXYL)CARBONYL]AMINO] N [2 (6 OXO 6H DIBENZO [CD,G]INDAZOL 2 YL)ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[(TERT BUTOXYL)CARBONYL]AMINO] N [2 (7 CHLORO 6 OXO 6H DIBENZO [CD,G]INDAZOL 2 YL) ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[2 (DIMETHYLAMINO)ACETYL]AMINO] N [2 (6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL)ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[2 (DIMETHYLAMINO)ACETYL]AMINO] N [2 (7 CHLORO 6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL) ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[[4 [[(TERT BUTOXYL)CARBONYL]AMINO] 1 METHYL 2 PYRROLYL]CARBONYL]AMINO] N [2 (6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL]ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[[4 [[(TERT BUTOXYL)CARBONYL]AMINO] 1 METHYL 2 PYRROLYL]CARBONYL]AMINO] N [2 (7 CHLORO 6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL)ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[[4 [[2 (DIMETHYLAMINO)ACETYL]AMINO] 1 METHYL 2 PYRROLYL]CARBONYL]AMINO] N [2 (6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL)ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[[4 [[2 (DIMETHYLAMINO)ACETYL]AMINO] 1 METHYL 2 PYRROLYL]CARBONYL]AMINO] N [2 (7 CHLORO 6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL)ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 [[[4 [[2 (DIMETHYLAMINO)ACETYL]AMINO] 1 METHYL 2 PYRROLYL]CARBONYL]AMINO] N [2 [7 [[(2 DIMETHYLAMINO)ETHYL]AMINO] 6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL]ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 AMINO N [2 (6 OXO 6H DIBENZO[CD,G]INDAZOL 2 YL) ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 4 AMINO N [2 (7 CHLORO 6 OXO 6H DIBENZO [CD,G]INDAZOL 2 YL)ETHYL] 1 METHYLPYRROLE 2 CARBOXAMIDE; 7 CHLORO 2 (2 AMINOETHYL)ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; 7 CHLORO 2 (2 HYDROXYETHYL)ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; AMIDE; ANTINEOPLASTIC AGENT; CONGOCIDINE; CONGOCIDINE DERIVATIVE; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE II ALPHA; DOUBLE STRANDED DNA; DOXORUBICIN; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CELL GROWTH; CONTROLLED STUDY; COVALENT BOND; CYTOTOXICITY; DNA CLEAVAGE; DNA DENATURATION; DRUG DESIGN; DRUG DNA BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MELTING POINT; MOLECULAR DOCKING;

AMIDES; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; DNA; DRUG DESIGN; HUMANS; INTERCALATING AGENTS; K562 CELLS; NETROPSIN; PYRROLES;

EID: 77953126769     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2010.04.028     Document Type: Article

References (37)

1. Corbett A.H., and Osheroff N. Chem. Res. Toxicol. 6 (1993) 585
2. Malisza K.L., and Hasinoff B.B. Arch. Biochem. Biophys. 321 (1995) 51
3. Leteurtre F., Kohlhagen G., Paul K.D., and Pommier Y. J. Natl. Cancer Inst. 86 (1994) 1239
4. Capranico G., Palumbo M., Tinelli S., Mabilia M., Pozzan A., and Zunino F. J. Mol. Biol. 28 (1994) 1218
5. Liang H., Wu X., Guziec L.J., Guziec Jr. F.S., Larson K.K., Lang J., Yalowich J.C., and Hasinoff B.B. J. Chem. Inf. Model. 46 (2006) 1827
6. Hasinoff B.B., Liang H., Wu X., Guziec L.J., Guziec Jr. F.S., and Yalowich J.C. Bioorg. Med. Chem. 16 (2008) 3959
7. Hasinoff B.B., Zhang R., Wu X., Guziec L.J., Guziec Jr. F.S., Marshall K., and Yalowich J.C. Bioorg. Med. Chem. 17 (2009) 4575
8. Bailly C., and Chaires J.B. Bioconjug. Chem. 9 (1998) 513
9. Bourdouxhe C., Colson P., Houssier C., Henichart J.P., Waring M.J., Denny W.A., and Bailly C. Anticancer Drug Des. 10 (1995) 131
10. Bourdouxhe-Housiaux C., Colson P., Houssier C., Waring M.J., and Bailly C. Biochemistry 35 (1996) 4251
11. David-Cordonnier M.H., Hildebrand M.P., Baldeyrou B., Lansiaux A., Keuser C., Benzschawel K., Lemster T., and Pindur U. Eur. J. Med. Chem. 42 (2007) 752
12. Pindur U., Jansen M., and Lemster T. Curr. Med. Chem. 12 (2005) 2805
13. Carrasco C., Helissey P., Haroun M., Baldeyrou B., Lansiaux A., Colson P., Houssier C., Giorgi-Renault S., and Bailly C. ChemBioChem 4 (2003) 50
14. Liang H., Wu X., Yalowich J.C., and Hasinoff B.B. Mol. Pharmacol. 73 (2008) 686
15. Pommier Y., Pourquier P., Fan Y., and Strumberg D. Biochim. Biophys. Acta 1400 (1998) 83
16. Fortune J.M., and Osheroff N. Prog. Nucl. Acid Res. Mol. Biol. 64 (2000) 221
17. Li T.K., and Liu L.F. Annu. Rev. Pharmacol. Toxicol. 41 (2001) 53
18. Hasinoff B.B., Kozlowska H., Creighton A.M., Allan W.P., Thampatty P., and Yalowich J.C. Mol. Pharmacol. 52 (1997) 839
19. Burden D.A., Froelich-Ammon S.J., and Osheroff N. Methods Mol. Biol. 95 (2001) 283
20. Hasinoff B.B., Wu X., Begleiter A., Guziec L., Guziec Jr. F.S., Giorgianni A., Yang S., Jiang Y., and Yalowich J.C. Cancer Chemother. Pharmacol. 57 (2006) 221
21. Orlowski S., Belehradek Jr. J., Paoletti C., and Mir L.M. Biochem. Pharmacol. 37 (1988) 4727
22. Fattman C., Allan W.P., Hasinoff B.B., and Yalowich J.C. Biochem. Pharmacol. 52 (1996) 635
23. Ritke M.K., Allan W.P., Fattman C., Gunduz N.N., and Yalowich J.C. Mol. Pharmacol. 46 (1994) 58
24. Ritke M.K., Roberts D., Allan W.P., Raymond J., Bergoltz V.V., and Yalowich J.C. Br. J. Cancer 69 (1994) 687
25. Leonard G.A., Hambley T.W., McAuley-Hecht K., Brown T., and Hunter W.N. Acta Crystallogr., Sect. D 49 (1993) 458
26. Balendiran K., Rao S.T., Sekharudu C.Y., Zon G., and Sundaralingam M. Acta Crystallogr., Sect. D 51 (1995) 190
27. Bailly C., Pommery N., Houssin R., and Henichart J.P. J. Pharm. Sci. 78 (1989) 910
28. Rene B., Fosse P., Khelifa T., Jacquemin-Sablon A., and Bailly C. Mol. Pharmacol. 49 (1996) 343
29. Boitte N., Pommery N., Colson P., Houssier C., Waring M.J., Henichart J.P., and Bailly C. Anticancer Drug Des. 12 (1997) 481
30. Hasinoff B.B., Wu X., Krokhin O.V., Ens W., Standing K.G., Nitiss J.L., Sivaram T., Giorgianni A., Yang S., Jiang Y., and Yalowich J.C. Mol. Pharmacol. 67 (2005) 937
31. Hasinoff B.B., Kuschak T.I., Creighton A.M., Fattman C.L., Allan W.P., Thampatty P., and Yalowich J.C. Biochem. Pharmacol. 53 (1997) 1843
32. Sissi C., Leo E., Moro S., Capranico G., Mancia A., Menta E., Krapcho A.P., and Palumbo M. Biochem. Pharmacol. 67 (2004) 631
33. Priebe W., Fokt I., Przewloka T., Chaires J.B., Portugal J., and Trent J.O. Methods Enzymol. 340 (2001) 529
34. McGhee J.D. Biopolymers 15 (1976) 1345
35. gold 3.2, CCDC Software Ltd, Cambridge, UK.
36. sybyl 7.3, Tripos Inc., 1699 South Hanley Rd., St. Louis, MO, 63144, USA.
37. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., and Taylor R.D. Proteins 52 (2003) 609